select trial semaglutide nejm FLOWing with the SemagluTIDE — NephJC

New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss

20.47

★★★★☆4.8 (126)

A newly approved 7.2-mg dose of injectable semaglutide lowered weight by 3 percentage points more than the standard 2.4-mg dose in clinical trials. "No formal medical criteria have been established for escalating

23.73

★★★★★4.9 (98)

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

24.51

★★★★★5.0 (157)

The SELECT trial. Semaglutide 2.4mg. The headline: "20% reduction in major cardiovascular events." Here is what 20% actually means. The placebo group had an 8% event rate. The semaglutide group had a

28.58

★★★★★4.7 (84)

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

28.53

★★★★★4.9 (203)

❤️ Heart protection that works even without diabetes. The SELECT trial proved semaglutide 2.4 mg cut major cardiovascular events by 20% in people who had heart disease + overweight/obesity but no diabetes

25.37

★★★★★5.0 (176)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Wilding - 2022 - Diabetes, Obesity and Metabolism

26.35

★★★★★4.8 (132)